JP2024544532A5 - - Google Patents

Info

Publication number
JP2024544532A5
JP2024544532A5 JP2024527533A JP2024527533A JP2024544532A5 JP 2024544532 A5 JP2024544532 A5 JP 2024544532A5 JP 2024527533 A JP2024527533 A JP 2024527533A JP 2024527533 A JP2024527533 A JP 2024527533A JP 2024544532 A5 JP2024544532 A5 JP 2024544532A5
Authority
JP
Japan
Prior art keywords
oligonucleotide
pdl1
antisense
hbv
pharmaceutical combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527533A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024544532A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/081355 external-priority patent/WO2023083906A2/en
Publication of JP2024544532A publication Critical patent/JP2024544532A/ja
Publication of JP2024544532A5 publication Critical patent/JP2024544532A5/ja
Pending legal-status Critical Current

Links

JP2024527533A 2021-11-11 2022-11-09 Hbvの処置のための医薬組合せ Pending JP2024544532A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21207715 2021-11-11
EP21207715.0 2021-11-11
PCT/EP2022/081355 WO2023083906A2 (en) 2021-11-11 2022-11-09 Pharmaceutical combinations for treatment of hbv

Publications (2)

Publication Number Publication Date
JP2024544532A JP2024544532A (ja) 2024-12-03
JP2024544532A5 true JP2024544532A5 (cg-RX-API-DMAC7.html) 2025-11-05

Family

ID=78598914

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527533A Pending JP2024544532A (ja) 2021-11-11 2022-11-09 Hbvの処置のための医薬組合せ

Country Status (10)

Country Link
US (1) US20250263705A2 (cg-RX-API-DMAC7.html)
EP (1) EP4430184A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024544532A (cg-RX-API-DMAC7.html)
KR (1) KR20240101580A9 (cg-RX-API-DMAC7.html)
CN (1) CN118284695A (cg-RX-API-DMAC7.html)
AU (1) AU2022384619A1 (cg-RX-API-DMAC7.html)
CA (1) CA3234478A1 (cg-RX-API-DMAC7.html)
IL (1) IL312635A (cg-RX-API-DMAC7.html)
MX (1) MX2024005399A (cg-RX-API-DMAC7.html)
WO (1) WO2023083906A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240131441A (ko) 2022-01-10 2024-08-30 오스퍼바이오 테라퓨틱스 인크. B형 간염 바이러스(hbv) 발현의 조절
EP4756027A1 (en) * 2023-08-04 2026-06-10 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Double-stranded ribonucleic acid targeting pd-l1
TW202612708A (zh) * 2024-05-22 2026-04-01 美商浩博生物醫藥有限公司 組合治療

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
EP1015469B2 (en) 1997-09-12 2015-11-18 Exiqon A/S Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues
BRPI0008131B8 (pt) 1999-02-12 2021-05-25 Daiichi Sankyo Co Ltd composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno
ATE356824T1 (de) 1999-05-04 2007-04-15 Santaris Pharma As L-ribo-lna analoge
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Rna 간섭의 rna 서열 특이적인 매개체
CN100523215C (zh) 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
US20050159378A1 (en) 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
WO2003040395A2 (en) 2001-11-07 2003-05-15 Applera Corporation Universal nucleotides for nucleic acid analysis
EP2284269B1 (en) 2002-11-18 2017-08-09 Roche Innovation Center Copenhagen A/S Antisense design
AU2004221760B2 (en) 2003-03-21 2010-03-18 Roche Innovation Center Copenhagen A/S Short interfering RNA (siRNA) analogues
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
ES2459368T3 (es) 2004-12-17 2014-05-09 Anadys Pharmaceuticals, Inc. Compuestos de 3H-oxazolo y 3H-tiazolo[4,5-d]pirimidin-2-ona 3,5-disustituidos y 3,5,7-trisustituidos y profármacos de los mismos
WO2007030167A1 (en) 2005-09-02 2007-03-15 Nastech Pharmaceutical Company Inc. Modification of double-stranded ribonucleic acid molecules
WO2007085485A2 (en) 2006-01-27 2007-08-02 Santaris Pharma A/S Lna modified phosphorothiolated oligonucleotides
DE602007009487D1 (de) 2006-01-27 2010-11-11 Isis Pharmaceutical Inc 6-modifizierte bicyclische nukleinsäureanaloga
ES2556128T3 (es) 2006-03-23 2016-01-13 Roche Innovation Center Copenhagen A/S ARN interfiriente pequeño internamente segmentado
EP2505646A1 (en) 2006-05-05 2012-10-03 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of CRP
CA2651453C (en) 2006-05-11 2014-10-14 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
EP2410053B2 (en) 2006-10-18 2020-07-15 Ionis Pharmaceuticals, Inc. Antisense compounds
US8580756B2 (en) 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
DK2170917T3 (da) 2007-05-30 2012-10-08 Isis Pharmaceuticals Inc N-Substituerede bicycliske nukleinsyreanaloge med aminomethylenbro
WO2008154401A2 (en) 2007-06-08 2008-12-18 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
AU2008272918B2 (en) 2007-07-05 2012-09-13 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
WO2009067647A1 (en) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Carbocyclic alpha-l-bicyclic nucleic acid analogs
WO2010033225A2 (en) 2008-09-22 2010-03-25 Dicerna Pharmaceuticals, Inc. Compositions and methods for the specific inhibition of gene expression by dsrna possessing modifications
WO2010039543A2 (en) 2008-09-23 2010-04-08 Traversa Therapeutics, Inc. Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
WO2010036698A1 (en) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
KR20110110776A (ko) 2008-12-18 2011-10-07 다이서나 파마수이티컬, 인크. 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
WO2010093788A2 (en) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Multiplex dicer substrate rna interference molecules having joining sequences
US8927513B2 (en) 2009-07-07 2015-01-06 Alnylam Pharmaceuticals, Inc. 5′ phosphate mimics
EP2462153B1 (en) 2009-08-06 2015-07-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
US8846637B2 (en) 2010-06-08 2014-09-30 Isis Pharmaceuticals, Inc. Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
US10017764B2 (en) 2011-02-08 2018-07-10 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US20140303235A1 (en) 2011-08-11 2014-10-09 Isis Pharmaceuticals, Inc. Linkage modified gapped oligomeric compounds and uses thereof
EP2850092B1 (en) 2012-04-09 2017-03-01 Ionis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
CA2889044A1 (en) 2012-11-15 2014-05-22 Roche Innovation Center Copenhagen A/S Anti apob antisense conjugate compounds
EP2928877B1 (en) 2012-12-06 2020-01-22 Merck Sharp & Dohme Corp. Disulfide masked prodrug compositions and methods
PL2992098T3 (pl) 2013-05-01 2019-09-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji hbv i ttr
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
CN107109405A (zh) 2014-06-06 2017-08-29 索尔斯蒂斯生物有限公司 具有生物可逆性和非生物可逆性基团的多核苷酸构建体
EP3204392A1 (en) 2014-10-11 2017-08-16 F. Hoffmann-La Roche AG Compounds for use in the treatment of infectious diseases
TWI769565B (zh) 2014-11-10 2022-07-01 美商阿尼拉製藥公司 B型肝炎病毒(HBV)iRNA組成物及其用途方法
HUE053704T2 (hu) 2014-12-08 2021-07-28 Hoffmann La Roche 3-szubsztitutált 5-amino-6H-tiazolo[4,5-d]pirimidin-2,7-dion vegyületek vírusfertõzések kezelésére és megelõzésére
EP3865576A1 (en) 2014-12-15 2021-08-18 Dicerna Pharmaceuticals, Inc. Ligand-modified double-stranded nucleic acids
CA3013683C (en) 2016-03-14 2021-07-13 F. Hoffmann-La Roche Ag Oligonucleotides for reduction of pd-l1 expression
WO2018098328A1 (en) 2016-11-23 2018-05-31 Alnylam Pharmaceuticals, Inc. Modified rna agents with reduced off-target effect
EP3684377B1 (en) 2017-10-20 2022-12-07 Dicerna Pharmaceuticals, Inc. Methods for treating hepatitis b infection
MA55375A (fr) * 2019-03-20 2022-01-26 Arbutus Biopharma Corp Méthodes thérapeutiques de traitement de l'hépatite b
EP4081639A1 (en) * 2019-12-24 2022-11-02 F. Hoffmann-La Roche AG Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
WO2021178612A1 (en) * 2020-03-05 2021-09-10 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
JP2023536999A (ja) * 2020-08-05 2023-08-30 エフ. ホフマン-ラ ロシュ アーゲー B型肝炎患者のオリゴヌクレオチド処置

Similar Documents

Publication Publication Date Title
JP6924744B2 (ja) B型肝炎ウイルスに対する組成物および薬剤ならびにその使用
CN109843902B (zh) 用于B型肝炎病毒感染的RNAi剂
JP2024153797A5 (cg-RX-API-DMAC7.html)
JP7763907B2 (ja) B型肝炎ウイルス感染のためのRNAi薬
TWI881004B (zh) 用於治療hbv之靶向hbv的治療性寡核苷酸及tlr7促效劑之醫藥組合
JP2018520685A5 (cg-RX-API-DMAC7.html)
US20240052350A1 (en) Oligonucleotide and use thereof against hepatitis b virus and hepatitis d virus
JP2023519246A5 (cg-RX-API-DMAC7.html)
CN113750112A (zh) 治疗b型肝炎和d型肝炎病毒感染的方法
JP2025500860A5 (cg-RX-API-DMAC7.html)
JP2023509870A5 (cg-RX-API-DMAC7.html)
WO2018089914A1 (en) Oligonucleotide targeting strategy for hbv cccdna
Goodarzi et al. Organ distribution and stability of phosphorothioated oligodeoxyribonucleotides in mice
KR20240101580A (ko) Hbv 치료를 위한 약학 조합물
US20230123601A1 (en) Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv
CN114057816B (zh) 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用
JP2024527380A5 (cg-RX-API-DMAC7.html)
RU2024115590A (ru) Фармацевтические комбинации для лечения hbv
CN121003688A (zh) 一种dsRNA与干扰素的联合治疗
HK40065449A (en) Methods for the treatment of hepatitis b and hepatitis d virus infections
HK40110728A (en) Pharmaceutical combinations for treatment of hbv
RU2021102269A (ru) Олигонуклеотиды для модуляции экспрессии rtel1
EA044937B1 (ru) АГЕНТЫ РНКи ПРОТИВ ИНФЕКЦИИ, ВЫЗВАННОЙ ВИРУСОМ ГЕПАТИТА В
HK40009627B (en) Rnai agents for hepatitis b virus infection